| Disease |
| Disease |
Method |
Sample |
Expression pattern |
Dysfunction type |
Description |
PMID |
Source |
| prostate cancer |
N/A |
N/A |
N/A |
regulation |
That same year, Chung et al reported PCa susceptibility SNPs within a 13 kb intron-less lincRNA also on 8q24, which they termed PRNCR1. |
24146262 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
regulation |
Susceptibility marker oncogene |
24373479 |
LncRNADisease
|
| prostate cancer |
N/A |
N/A |
N/A |
regulation |
The focus of this Nature report13 is on two PCa-associated lncRNAs: PCGEM1 and PRNCR1. They cooperate in regulating the function of the male hormone receptor, the androgen receptor (AR), which plays central role in PCa onset and progression. AR pathway is activated in advanced CaPs including castration-resistant prostate cancer (CRPC). |
24713835 |
LncRNADisease
|
| colorectal cancer |
PCR-RFLP etc. |
CRC tissue |
differential expression |
N/A |
In overall analyses, we found that the rs13252298 and rs1456315 were associated with significantly decreased risks of CRC. In stratification analyses, we found that CRC patients carrying the rs1456315G were likely to have a tumor size of greater than 5 cm (G vs. A: adjusted OR = 1.56, 95% CI: 1.10-2.23). Additionally, patients with the rs7007694C and rs16901946G had decreased risks to develop poorly differentiated CRC, whereas patients with the rs1456315G had an increased risk to develop poorly differentiated CRC. |
24330491 |
Lnc2Cancer
|
| gastric cancer |
qPCR etc. |
gastric cancer tissue |
differential expression |
mutation |
We found that patients with the rs13252298AG genotype displayed a 1.50-fold increased risk of GC. Interestingly, the rs7007694CT and CC and the rs1456315GG genotypes displayed a decreased risk of GC. Our results suggest that SNPs in the lncRNA PRNCR1 may be a biomarker for the etiology of GC |
26206497 |
Lnc2Cancer
|
| colorectal cancer |
qPCR, Flow cytometry assay etc. |
CRC tissue, cell lines (SW620, HCT116, SW480, LoVo, HT29) |
up-regulated |
expression |
PRNCR1 was significantly overexpressed in CRC tissues compared with the expression in adjacent tissues, with an average fold increase of 10.55. Additionally, a high level of PRNCR1 was associated with large tumor volume. Compared with the normal human colorectal epithelial cell line (FHC), PRNCR1 was upregulated in most CRC cell lines (HCT116, SW480, LoVo and HT 29). |
26530130 |
Lnc2Cancer
|
| prostate cancer |
qPCR, Northern blot etc. |
cell lines (LNCaP, 22Rv1, PC-3 etc.) |
up-regulated |
N/A |
PRNCR1 expression was upregulated in some of the PC cells as well as precursor lesion prostatic intraepithelial neoplasia. Knockdown of PRNCR1 by siRNA attenuated the viability of PC cells and the transactivation activity of androgen receptor, which indicates that PRNCR1 could be involved in prostate carcinogenesis possibly through androgen receptor activity. |
20874843 |
Lnc2Cancer
|
| prostate cancer |
qPCR, RIP etc. |
prostate cancer tissue,cell lines (LNCaP, LNCaP-cds1, LNCaP-cds2, CWR22Rv1 etc.), tissues (prostate tumour tissues) |
up-regulated |
expression |
Here we report that two lncRNAs highly overexpressed in aggressive prostate cancer, PRNCR1 (also known as PCAT8) and PCGEM1, bind successively to the androgen receptor and strongly enhance both ligand-dependent and ligand-independent androgen-receptor-mediated gene activation programs and proliferation in prostate cancer cells. |
23945587 |
LncRNADisease Lnc2Cancer
|
| prostate cancer |
RNA-seq, qRT-PCR |
N/A |
N/A |
N/A |
not implicated in castration resistant prostate cancer. |
24727738 |
|
| |